Overview
- On Wednesday, July 1, 2026, Alibaba and its U.S. payment processor agreed to a $600 million payment and a non-prosecution agreement to resolve U.S. allegations about illegal pharmaceuticals, controlled substances, regulated chemicals, and pill-making equipment.
- As part of the deal Alibaba acknowledged that between January 2016 and December 2024 roughly 80,000 unlawful sales occurred on its platforms and that company compliance controls failed to stop those listings.
- U.S. agencies including the FDA, the FDIC, and IRS Criminal Investigation carried out more than 40 undercover purchases of products illegal to import, a probe that fed the Justice Department’s case.
- The settlement names a U.S. payment processor for failing to block illicit transactions, with the AP identifying AUS Merchant Services while some outlets say the processor was not publicly named, showing a shift toward policing payment intermediaries.
- The $600 million hit is manageable against Alibaba’s recent revenue but resolves criminal exposure and may sharpen civil, reputational, and operational scrutiny for the company as regulators and investors weigh longer-term fallout and past concerns about fentanyl precursors.